Publications

Found 1 results
Filters: Author is C.D. Yu  [Clear All Filters]
2012
Q. Chen, Li, W. J., Wan, Y. Y., Yu, C. D., and Li, W. G., Fibroblast growth factor receptor 4 Gly388Arg polymorphism associated with severity of gallstone disease in a Chinese population, vol. 11, pp. 548-555, 2012.
Bange J, Prechtl D, Cheburkin Y, Specht K, et al. (2002). Cancer progression and tumor cell motility are associated with the FGFR4 Arg388 allele. Cancer Res. 62: 840-847. PMid:11830541 Buch S, Schafmayer C, Volzke H, Becker C, et al. (2007). A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat. Genet. 39: 995-999. http://dx.doi.org/10.1038/ng2101 PMid:17632509 Buch S, Schafmayer C, Volzke H, Seeger M, et al. (2010). Loci from a genome-wide analysis of bilirubin levels are associated with gallstone risk and composition. Gastroenterology 139: 1942-1951. http://dx.doi.org/10.1053/j.gastro.2010.09.003 PMid:20837016 Chan T, Yaghoubian A, Rosing D, Lee E, et al. (2008). Total bilirubin is a useful predictor of persisting common bile duct stone in gallstone pancreatitis. Am. Surg. 74: 977-980. PMid:18942626 Choi M, Moschetta A, Bookout AL, Peng L, et al. (2006). Identification of a hormonal basis for gallbladder filling. Nat. Med. 12: 1253-1255. http://dx.doi.org/10.1038/nm1501 PMid:17072310 Donovan JM (1999). Physical and metabolic factors in gallstone pathogenesis. Gastroenterol. Clin. North Am. 28: 75-97. http://dx.doi.org/10.1016/S0889-8553(05)70044-3 Falvella FS, Frullanti E, Galvan A, Spinola M, et al. (2009). FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung. Int. J. Cancer 124: 2880- 2885. http://dx.doi.org/10.1002/ijc.24302 PMid:19296538 Hylemon PB, Zhou H, Pandak WM, Ren S, et al. (2009). Bile acids as regulatory molecules. J. Lipid Res. 50: 1509-1520. http://dx.doi.org/10.1194/jlr.R900007-JLR200 PMid:19346331    PMCid:2724047 Jiang ZY, Han TQ, Suo GJ, Feng DX, et al. (2004). Polymorphisms at cholesterol 7alpha-hydroxylase, apolipoproteins B and E and low density lipoprotein receptor genes in patients with gallbladder stone disease. World J. Gastroenterol. 10: 1508-1512. PMid:15133863 Johnston DE and Kaplan MM (1993). Pathogenesis and treatment of gallstones. N. Engl. J. Med. 328: 412-421. http://dx.doi.org/10.1056/NEJM199302113280608 PMid:8421460 Jones S (2008). Mini-review: endocrine actions of fibroblast growth factor 19. Mol. Pharm. 5: 42-48. http://dx.doi.org/10.1021/mp700105z PMid:18179175 Lammert F and Sauerbruch T (2005). Mechanisms of disease: the genetic epidemiology of gallbladder stones. Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 423-433. http://dx.doi.org/10.1038/ncpgasthep0257 Miyasaka K, Takata Y and Funakoshi A (2002). Association of cholecystokinin A receptor gene polymorphism with cholelithiasis and the molecular mechanisms of this polymorphism. J. Gastroenterol. 37 (Suppl 14): 102-106. PMid:12572876 Russell DW and Setchell KD (1992). Bile acid biosynthesis. Biochemistry 31: 4737-4749. http://dx.doi.org/10.1021/bi00135a001 PMid:1591235 Srivastava A, Pandey SN, Choudhuri G and Mittal B (2008). Role of genetic variant A-204C of cholesterol 7alpha-hydroxylase (CYP7A1) in susceptibility to gallbladder cancer. Mol. Genet. Metab. 94: 83-89. http://dx.doi.org/10.1016/j.ymgme.2007.11.014 PMid:18178499 Strasberg SM (1997). Cholelithiasis and acute cholecystitis. Baillieres Clin. Gastroenterol. 11: 643-661. http://dx.doi.org/10.1016/S0950-3528(97)90014-2 Strasberg SM and Clavien PA (1992). Cholecystolithiasis: lithotherapy for the 1990s. Hepatology 16: 820-839. http://dx.doi.org/10.1002/hep.1840160332 PMid:1387104 Wang J, Stockton DW and Ittmann M (2004). The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin. Cancer Res. 10: 6169-6178. http://dx.doi.org/10.1158/1078-0432.CCR-04-0408 PMid:15448004 Wang J, Yu W, Cai Y, Ren C, et al. (2008). Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia 10: 847-856. PMid:18670643    PMCid:2481572 Ye Y, Shi Y, Zhou Y, Du C, et al. (2010). The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression. Ann. Surg. Oncol. 17: 3354-3361. http://dx.doi.org/10.1245/s10434-010-1323-6 PMid:20844967 Yu C, Wang F, Kan M, Jin C, et al. (2000). Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J. Biol. Chem. 275: 15482-15489. http://dx.doi.org/10.1074/jbc.275.20.15482 PMid:10809780 Yu C, Wang F, Jin C, Huang X, et al. (2005). Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids. J. Biol. Chem. 280: 17707-17714. http://dx.doi.org/10.1074/jbc.M411771200 PMid:15750181